Anybody see this NEWS?
SOR, ON / ACCESSWIRE / December 14, 2015 / The Wealthy Biotech Trader (or "WBT"), an investment newsletter focused on showing everyday investors new opportunities in rapidly growing, little-known biotech, pharma, medical device and general healthcare stocks making news and subsequent market moves, would like to mention a few highlights from 2014/ 2015 in the crazy world of biotech investing.
In 2014 51 new medicines were approved by the FDA, the most in almost 20 years. A whopping 8 of those approvals were new drugs for cancer treatment--since 1990, cancer death rates have declined nearly 22%--and approximately 83% of the survival gains are attributable to new treatments.
And although 2015 is shaping up to be another banner year for scientific and drug breakthroughs for cancer, there are a few areas in oncology (cancer treatment) that most pharma companies are having a very difficult time seeing any meaningful progress.
Pancreatic cancer is by most measures the deadliest of the 200+ cancers as evidenced by its 7% 5-year survival rate--meaning only 7% of people diagnosed with this horrific killer will live longer than 5 years. 75% of patients die in the first year, and only a few out of 100 will live longer that 10 years. In nearly 40 years there has been virtually no improvement in the overall survival rates in those diagnosed with pancreatic cancer. Until now?
One tiny Australian biotech company is working on a novel compound / drug that they have recently stated could have a major impact on this deadly disease. The company is pre-clinical, but has just released very compelling news of shrinking pancreatic cancer tumors in mice by 84% in only 26 days (click the next paragraph to read the news).
Propanc Heath Group (PPCH) News: Propanc Demonstrates Significant Anti-Tumor Efficacy in Pancreatic and Ovarian Cancer Preclinical Models; Files Patent Specifying New Therapeutic Target Dose Range
Investors will be watching PPCH like a hawk over the next 1-3 months as they wrap up their "animal studies" and prepare their "Initial New Drug" application with the FDA. The company has stated in news releases they have the cash in the bank to get to that point, which could be a huge inflection point for shareholder value creation if approved by the FDA.
